Sorafenib has been shown to be effective in patients with advanced hepatocellular carcinoma. The median survival and time to radiologic progression were nearly 3 months longer for patients treated with sorafenib than for those given placebo.
Filed under: kinase | Tagged: bayer, multikinase, Nexavar, onyx, PDGFR, phase iii, raf, RET, sorafenib, VEGFR | Comments Off
